{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 71,
  "pageCount": 415,
  "prevPage": 70,
  "nextPage": 72,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses specific quotes from an investigator to undermine the validity of clinical trial results and highlight potential adverse events.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/71",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-71",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Moreover, the investigator's comments cast grave doubt on the validity of the withdrawal study, which showed an abrupt spike in HQ-CT scores in the placebo group for such a \"slow drug.\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-7f83edc6eaef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.848,
        "x": 0.076,
        "y": 0.208
      },
      "kind": "list",
      "text": "In addition, the investigator stated the “drug takes a long time to work” – “in the first three months...there isn't a change...probably more towards 12 weeks...plateaus at about 35, 40 weeks...it's a slow drug.” We note that the phase 3 trial was only 13 weeks, and that other investigators found it odd and troubling that the purported hyperphagia improvements occurred far into the trial during the open-label phase. Moreover, the investigator's comments cast grave doubt on the validity of the withdrawal study, which showed an abrupt spike in HQ-CT scores in the placebo group for such a “slow drug.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5efce615-61e0-4d77-8ab1-236309d2de45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.848,
        "x": 0.076,
        "y": 0.418
      },
      "kind": "list",
      "text": "Stated that a pediatric patient “nearing 18” years of age was hospitalized for a cardiac event shortly after starting Vykat in the phase 3 trial – “a few months into - I think was C601”; “...severely unwell...he was hospitalized for severe pneumonia...he had heart and lung involvement.” The investigator stated the patient was at another trial site and was unable to confirm whether it was pulmonary edema, which strikes us as the likely presentation given Vykat's edema profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0dff90c-c13a-40ba-b31d-832f2996e996",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“drug takes a long time to work” – “in the first three months...there isn't a change...probably more towards 12 weeks...plateaus at about 35, 40 weeks...it's a slow drug.” — Trial investigator #8",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-82bd98993c2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.076,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e95c3ec1-37bc-4b4e-be75-d9c62cfc1a37",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.135,
        "w": 0.848,
        "x": 0.076,
        "y": 0.068
      },
      "kind": "title",
      "text": "Trial investigator #8 (cont'd): Not considered a KOL or published authority on PWS, but was an investigator across the phase 3, open-label, and withdrawal studies, as well as a key co-author on Vykat papers.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df1f5aaa-22ca-4365-9289-214ca1240eef",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "8b0584dd-8580-4a0d-9665-f20afcb4a91a",
      "evidence": "The slide uses expert testimony to expose contradictions in clinical trial data and safety reporting.",
      "confidence": 0.85
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}